Patient Advocacy Groups Welcome 40% Increase in Alzheimer’s NIH Research Funds Authorized by Congress

Patient Advocacy Groups Welcome 40% Increase in Alzheimer’s NIH Research Funds Authorized by Congress
The U.S. Congress last week authorized an additional 40 percent in funds for Alzheimer's disease (AD) research, boosting the fiscal 2017 total by $400 million to nearly $1.4 billion as part of a $2 billion year-over-year increase for the National Institutes of Health (NIH). The final package won praise from the nonprofit Global Alzheimer's Platform Foundation (GAP), a Washington-based entity launched in 2015 by UsAgainstAlzheimer's and the Global CEO Initiative (CEOi) on Alzheimer's Disease. GAP works with leading researchers, drug firms, nonprofit groups and governments to slash the time, cost and risk involved in Alzheimer's clinical trials and speed up approval of innovative medicines and other therapies. The foundation aims to build a standing global clinical trial platform of willing participants through novel recruitment techniques, coupled with a network of participating high-performance clinical trial sites. "Scientific research and the related clinical trials funded by the NIH are the only way we can find a cure for Alzheimer's disease," GAP Foundation President John Dwyer said in a press release. "A critical issue that delays scientific research is recruiting enough participants for clinical trials. This needed funding increase will help fill that void." George Vradenburg, co-founder and chair of U
Subscribe or to access all post and page content.

One comment

Leave a Comment

Your email address will not be published. Required fields are marked *